News
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap
Scripps Health and UT Health San Antonio purchase Oncora’s software to improve physician documentation and enhance personalized cancer care
Melior Announces Substantial Additions to Its Management and Scientific Team
• Dr. Ken Kilgore joins Melior as VP of Scientific Operations
• Dr. Hongyan Li joins Melior as Director of Oncology
• Dr. Vivian Cong rises to VP of Research & Development
WellTrackONE Corporation releases Targeted Risk Adjustment Coding system (TRAC)
TRAC will help with HCC RAF scores, lost revenue opportunities and avoidance of RAC/RADV audit penalties
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
– Immunome Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application –
– Immunome Continues to Progress IMM-BCP-01 Towards Phase 1b Clinical Trial –
– Ongoing Progress on Oncology Pipeline, Including Lead Program Targeting IL-38, a Novel Innate Immunome Checkpoint –